|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
101,000,000 |
Market
Cap: |
665.59(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.7528 - $16.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 9.5 |
Insider 3/6 Months : 10.1 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
230,000 |
230,000 |
330,000 |
Total Buy Value |
$0 |
$310,500 |
$310,500 |
$455,990 |
Total People Bought |
0 |
2 |
2 |
3 |
Total Buy Transactions |
0 |
2 |
2 |
3 |
Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
Total People Sold |
0 |
0 |
1 |
5 |
Total Sell Transactions |
0 |
0 |
1 |
9 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lupher, Jr. Mark L. |
|
|
2024-02-07 |
4 |
B |
$1.35 |
$175,500 |
D/D |
130,000 |
130,000 |
0.01 |
171% |
|
Scopa James Paul |
|
|
2024-02-07 |
4 |
B |
$1.35 |
$135,000 |
D/D |
100,000 |
100,000 |
0.01 |
171% |
|
Seyedkazemi Setareh |
Chief Development Officer |
|
2023-09-15 |
4 |
S |
$1.52 |
$9,429 |
D/D |
(6,201) |
47,674 |
|
43% |
|
Rubinstein Linda M |
Chief Financial Officer |
|
2023-06-07 |
4 |
B |
$1.45 |
$145,490 |
D/D |
100,000 |
100,000 |
2.74 |
-41% |
|
Riley Brigit |
Chief Scientific Officer |
|
2023-03-15 |
4 |
S |
$0.78 |
$5,705 |
D/D |
(7,299) |
117,435 |
|
-113% |
|
Fischer Laurent |
CEO, President and Director |
|
2023-03-15 |
4 |
S |
$0.78 |
$32,232 |
D/D |
(41,239) |
692,141 |
|
-113% |
|
Soparkar Peter |
Chief Operating Officer |
|
2023-03-15 |
4 |
S |
$0.78 |
$10,442 |
D/D |
(13,360) |
265,891 |
|
-113% |
|
Fischer Laurent |
CEO, President and Director |
|
2022-09-19 |
4 |
S |
$1.07 |
$43,941 |
D/D |
(41,082) |
727,380 |
|
38% |
|
Seyedkazemi Setareh |
Chief Development Officer |
|
2022-09-19 |
4 |
S |
$1.07 |
$6,480 |
D/D |
(6,058) |
47,875 |
|
38% |
|
Riley Brigit |
Chief Scientific Officer |
|
2022-09-19 |
4 |
S |
$1.07 |
$7,772 |
D/D |
(7,266) |
118,734 |
|
38% |
|
Soparkar Peter |
See Remarks section |
|
2022-09-19 |
4 |
S |
$1.07 |
$14,232 |
D/D |
(13,305) |
273,251 |
|
38% |
|
Beckman Richard |
Chief Medical Officer |
|
2022-09-19 |
4 |
S |
$1.07 |
$4,570 |
D/D |
(4,272) |
39,061 |
|
38% |
|
Beckman Richard |
Chief Medical Officer |
|
2022-09-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
33,333 |
43,333 |
|
- |
|
Seyedkazemi Setareh |
Chief Development Officer |
|
2022-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,333 |
53,933 |
|
- |
|
Beckman Richard |
Chief Medical Officer |
|
2022-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
35,000 |
|
- |
|
Rakow John |
SVP, Genl Counsel, Acting CFOO |
|
2022-06-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
58,233 |
|
-8% |
|
Seyedkazemi Setareh |
Chief Development Officer |
|
2022-05-23 |
4 |
B |
$0.84 |
$16,800 |
D/D |
20,000 |
20,600 |
2.74 |
21% |
|
Beckman Richard |
Chief Medical Officer |
|
2022-05-17 |
4 |
B |
$0.82 |
$8,228 |
D/D |
10,000 |
10,000 |
2.74 |
6% |
|
Dsouza Rupert |
Chief Financial Officer |
|
2022-05-17 |
4 |
B |
$0.83 |
$8,272 |
D/D |
10,000 |
20,850 |
2.74 |
6% |
|
Graham Dawn |
Director |
|
2022-05-16 |
4 |
B |
$0.85 |
$25,578 |
D/D |
30,000 |
50,000 |
2.39 |
14% |
|
Dsouza Rupert |
Chief Financial Officer |
|
2022-05-13 |
4 |
B |
$0.86 |
$8,585 |
D/D |
10,000 |
10,850 |
2.74 |
16% |
|
Fischer Laurent |
CEO, President and Director |
|
2022-04-20 |
4 |
B |
$1.11 |
$27,800 |
D/D |
25,000 |
762,462 |
2.81 |
6% |
|
Soparkar Peter |
See Remarks section |
|
2022-04-19 |
4 |
B |
$1.14 |
$24,994 |
D/D |
21,925 |
280,556 |
2.74 |
- |
|
Seyedkazemi Setareh |
Chief Development OfficerOffic |
|
2022-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
600 |
|
-52% |
|
Fischer Laurent |
CEO, President and Director |
|
2021-12-09 |
4 |
B |
$1.85 |
$26,498 |
D/D |
14,323 |
737,462 |
2.81 |
-39% |
|
266 Records found
|
|
Page 1 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|